Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition
Executive Summary
A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said